INTRODUCTION
The lack of commercially available oral liquid dosage forms is an ongoing problem for health care providers in many practice settings. Pharmacists are often challenged to provide extemporaneous oral liquids. While these are most commonly provided for paediatric patients where non-standard doses are more easily and accurately measured by using a liquid formulation, adults unable to swallow tablets or capsules and patients receiving medicines via nasogastric or gastrostomy tubes will also benefit from these preparations (1) . The world's population is ageing and many people suffer from dysphagia either as a consequence of disease or as part of the ageing process. Elderly patients are more prone to diseases linked to dysphagia, such as Parkinson's disease and Alzheimer's and other dementias, stroke and cancer (2-4). Extemporaneous oral liquids are also needed where, for example, a commercially available oral liquid is discontinued or temporarily unavailable, such as Tamiflu® (oseltamivir) Oral Suspension (5,6).
A number of parameters need to be considered in the formulation of a stable oral liquid. These include chemical, physical, microbiological, therapeutic and toxicological stability evaluations not only taking account of the active pharmaceutical ingredient (API), but also the excipients and packaging of the drug product. The extemporaneous preparation of oral liquids can be complex due to the addition of excipients to improve patient adherence and / or the stability of the final product. Further, due to convenience and availability of ingredients, it is ________________________________________ common practice for oral liquids to be prepared from commercially available solid dosage forms such as a tablet or capsules. Therefore additional potential interactions may occur between the drug and the excipients in the solid dosage in the prepared oral liquid.
In addition to chemical stability, physical stability, microbial stability and palatability, excipient suitability (e.g. sugar free for diabetic patients) and interactions with packaging materials need to be considered in the preparation of a suitable extemporaneous oral liquid. These considerations are detailed in the discussion.
This review provides new evidence, since the previous review in 2006 (7), of stability data for extemporaneous oral liquids prepared from commercially available dosage forms including tablets, capsules and intravenous preparations. Further, the review outlines important stability considerations and the risk associated with modifying commercial products and provides guidelines to assist the pharmacist in preparing safe, effective and high quality oral liquids.
METHODS
A review protocol was developed with data identified from MEDLINE, EMBASE, Informit, Google Scholar, reference texts related to the field and reference lists of articles and abstracts from conference proceedings. Searches were current as of April 2013.
Only those liquid dosage forms prepared from commercially available dosage forms were considered, as this is most commonly encountered in practice, where access to raw material as the is not often convenient or even possible. As in the first review (7), only those preparations that included a chemical stability assessment via a stability-indicating high performance liquid chromatography (HPLC) method were included and the oral liquids were considered chemically stable if they retained ≥ 90% of the initial drug concentration. The reasons for this are detailed in the previous review (7). Those oral liquids that have been previously reported on in the first review have not been included in this paper. (Table 1) of oral liquids in practice, prepared by modification of commercial medications, including the methods, excipients, packaging and reasons for their extemporaneous preparation. The outcome of the chemical and physical stability studies conducted is also presented. The highlighted (shaded) areas in Table 1 indicate those preparations that have been further detailed in the discussion.
RESULTS

This review includes 42 examples
DISCUSSION
Of the 42 liquid dosage forms reviewed in the literature, all cases of instability were managed through the addition of specific excipients, illustrating that there is minimum risk associated with these dosage forms and that pharmacists taking cognisance of various factors such as drug stability, mechanisms and routes of degradation, and potential interactions with excipients in the tablets and/or capsules utilised in the formulation are further able to minimise the risk involved. The individual dosage forms displaying stability concerns are discussed below.
Omeprazole and lansoprazole oral liquid dosage forms
Stability concerns with lansoprazole (20) are related to a slightly acidic pH of the final formula due to Ora-Blend being buffered to a slightly acidic pH of ~4.2. However, this instability has been largely addressed by the addition of NaHCO3.
Further, omeprazole is now commercially available as a powder for oral suspension (ZEGERID® Powder for Oral Suspension) which contains NaHCO3, xylitol, sucrose, sucralose, xanthan gum, and flavourings.
Mercaptopurine oral liquid dosage forms
A study reported on the stability of mercaptopurine, a drug susceptible to oxidation, resulting in the formation of acidic degradants (23). A buffer was therefore investigated to address the increased acidity due to the formation of these degradants. However the buffer resulted in a decreased stability of mercaptopurine, due to the increased pH. This stability issue was addressed by the addition of the antioxidant ascorbic acid which increased the shelf-life from 5 to 11 weeks.
The authors recommended further studies on the microbial safety of these vehicles, since they did not contain preservatives; however this can be addressed by using commercially available vehicles such as Ora-Blend which are adequately preserved.
Temozolomide oral liquid dosage forms
Temozolomide is a prodrug, which after hydrolysis in an alkaline environment is converted to the active alkylating agent. Solid-state temozolomide is thus also susceptible to hydrolytic degradation under accelerated temperature and humidity conditions (40 ⁰C and 75% relative humidity), with a change in colour of the white powder first to pink and then brown, an indication that this chemical degradation has occurred. Temozolomide does however also exhibit polymorphism, with powder X-ray crystal structures confirming the identity of three crystalline polymorphs and a monohydrate. Although the powder X-ray diffraction pattern of the commercially available temozolomide is consistent with Form 1, which is non hygroscopic the discolouration of certain brands of tablets on storage raises the question as to which crystal form is present in these tablets (47) . Temozolomide oral liquid extemporaneously prepared from commercially available capsules in both (1:1) Ora-Plus: Ora-Sweet and Ora-Plus: Ora-Sweet SF was stored at room temperature (23 ºC) and at 4 ºC (36), with stability confirmed for 1 week in Ora-Plus: Ora-Sweet (1:1) and 2 weeks in Ora-Plus: Ora-Sweet SF at room temperature (23 ºC) and 60 days at 4⁰C. Because of the potential for polymorphism and the detection of crystals in the suspensions within a few days of storage at both temperatures, the excipient povidone K-30 was added to minimise this crystal growth, which if it does occur may result in inaccurate dosing.
The inclusion of povidone K-30 to prevent crystal formation and optimising the pH at 4 (citric acid) to reduce hydrolytic degradation produced a pharmaceutically acceptable suspension when stored under refrigeration.
Clopidogrel oral liquid dosage forms
Skillman et al (14) evaluated the stability of clopidogrel 5 mg/mL suspension prepared in OraPlus and Ora-Sweet and concluded that over 90 % of the initial clopidogrel concentration was retained after 60 days at room temperature or under refrigeration. However, the method used to measure clopidogrel concentration was not chirally selective and failed to consider the potential for isomeric inversion of the active Sclopidogrel to the inactive R-clopidogrel. A later study (14) highlighted the importance of the conversion of the acive S form to the inactive R enatiomer. This study determined that 1.5 % and 3 % of S-clopidogrel was converted to the R enantiomer after storage for 49 days at 4 ºC and 25 ºC respectively. These authors then used this data to estimate the shelf-life assuming 90 % of the original content and recommended an expiry of 1 month under refrigeration and 2 weeks at room temperature (25 ºC).
Packaging used in extemporaneous oral liquid preparations Ensom et al (19) reported on the stability of lansoprazole (3mg/mL) in extemporaneously compounded suspensions (see Table 2 ). The findings reported here are in contrast with those of a previous study (48) detailed in the first review (7), in which a lansoprazole suspension (3 mg/mL) was stable for only 8 hours when prepared from capsule contents mixed in 100 mL of 8.4% NaHCO3 and stored at room temperature (22°C) in amber-coloured, plastic oral syringes. Although the refrigerated (4°C) samples in that study were reported to be stable for only 14 days, the refrigerated samples in the current study were stable for 91 days. It has been suggested by the authors that the different storage containers, namely plastic syringes and glass bottles, may account for the difference in stability of lansoprazole suspensions, and that a substance present in the plastic syringes but not in the glass might have reduced the stability of lansoprazole. In addition it was also suggested that the amber syringes stored at room temperature would not have protected the lansoprazole from UV light to the same extent as the suspension stored in the refrigerator, where it is naturally dark (19).
Storage conditions for oral liquids
It is important to note that refrigerated solutions do not always show increased stability and can have increased problems of caking as demonstrated by the study by Aliabadi et al (23) with a refrigerated suspension of mercaptopurine. This emphasises the importance of stability studies for specific drugs and the benefits of using a vehicle containing appropriate suspending agents.
Considerations
in the extemporaneous preparation of oral liquids When considering the suitability of an extemporaneous oral liquid, a number of factors, in addition to chemical stability need to be considered (Table 2 ). This includes physical stability, microbial stability, palatability, excipient suitability (e.g. sugar free for diabetic patients), interactions with packaging materials, accurate compounding procedures including calculations and cost. 51, 52) , as is access to appropriate facilities and equipment and accurate calculations of ingredients in the final preparation. Some API's are extremely sensitive to light, showing significant degradation in only a few hours, therefore exposure to light needs to be minimised during preparation. The source of the water used has also been shown to cause problems (53). Assigning an appropriate beyond use date or shelflife in the absence of specific stability studies is also challenging, with many preparations given a very short shelf-life for safety purposes. (ix) dose calculations. A study on the stability of a 1 mg/ml tacrolimus suspension (34) has shown that careful consideration of the strength of the oral liquid (namely 1mg/mL as opposed to decimal amounts per mL) will facilitate several aspects of clinical care, For example, the 1:1 ratio of drug to suspension volume will decrease the frequency of patient medication errors, as it allows for a more simplified and straightforward drug administration. This will also facilitate easier discharge medication instructions or any follow-up discharge instruction in the outpatient clinic when confirming and verifying dosing. Further, incremental dosing with the 1 mg/ml suspension allows for more accurate adjustment of therapy based on monitoring blood levels and paediatric dosing could result in better patient adherence owing to the small volume required for dosing.
Commercially available oral liquid vehicles
Commercially available vehicles, such as OraPlus and Ora-Sweet and Ora-Sweet SF are a convenient resource for pharmacists, since many practice settings may not stock a wide variety of excipients and many of the stability studies in the literature on oral liquids prepared extemporaneously utilise these commercial vehicles, as seen in Table 1 . A number of medicines are stable at an acidic pH, for example thalidomide is not stable in a solution with a pH of greater than or equal to 6.0 (37). All of the above vehicles are buffered to a slightly acidic pH (pH~4.2) to reduce the degradation of medicinal agents through oxidation. The vehicles also contain effective preservatives, therefore microbial testing is not needed (22). Ora-Plus is a translucent, milky white oral suspending vehicle that can be diluted up to 50 % or more with other ingredients and still retain appropriate properties as a suspending agent. It also contains an antifoaming agent, simethicone, to allow for vigorous shaking of the suspension with minimal production of foam. Ora-Sweet syrup is a flavouring vehicle for oral extemporaneous preparations. It contains glycerin and sorbital to prevent "cap-lock", a problem associated with many syrups, due to sugar crystallization, and will retain its flavouring properties when diluted up to 50% with water or suspending agents. Ora-Sweet SF is a sugar-free version of Ora-Sweet with similar properties. Ora-Plus and either Ora-Sweet or Ora-Sweet SF can be combined in a 50/50 ratio to produce a pleasant tasting elegant suspension. The original formulas for the Ora-range of vehicles are available in the United States Pharmacopoeia/ National Formulary (USP/NF) and are referred to as Vehicle for Oral Solution NF (i.e. Ora-Sweet), Vehicle for Oral Suspension NF (i.e. Ora-Plus), and Vehicle for Oral Solution, Sugar Free NF (i.e. Ora-Sweet SF) (54).
A recent study (55) on the content uniformity of six different suspensions compounded from nifedipine tablets, showed that the suspensions compounded with methylcellulose 1% / syrup NF or hypromellose 1% required mixing by inverting the bottle 10 to15 times, while the commercially available suspension vehicles (namely, OraPlus/Ora-Sweet, Ora-Plus/Ora-Sweet SF and SyrSpend SF Cherry) complied with the pharmacopoeial content uniformity test if the bottle was inverted only three times. This highlights the benefits of utilising commercially available vehicles.
Further usefulness of commercially available vehicles is highlighted in a review of the stability of captopril oral liquids (53). Due to the susceptibility of captopril to oxidation, the use of water-based captopril solutions is not recommended. This is due to the potential for the variable quality of water, particularly in terms of its metal ion content, to facilitate the oxidative degradation of captopril. The previous review (7) detailed a number of studies and the associated stability concerns with compounding captopril oral liquids. It has been suggested that alternative therapeutic agents such as lisinopril and ramipril should be preferentially used due to their improved stability in oral formulations, or commercially available captopril oral liquids sourced.
Management of oral liquid preparations in practice
A recent review by Lam (56) on the extemporaneous preparation of oral liquid formulations for anticancer drugs showed that compounding formulae are available for only 46 % of oral anticancer agents and that there is a paucity of data in terms of stability, bioequivalence, and safety of these extemporaneously prepared oral formulations. The review detailed the challenges that health care providers, patients, and caregivers face with the limited availability of oral liquid formulations. Caregivers are often at an increased risk of exposure to these hazardous drugs when challenged with an oral tablet or capsule that the patient cannot swallow. The review also highlighted the important role that oncology pharmacists, as well as community pharmacists, can play as a resource for educating and monitoring patients receiving oral chemotherapy to ensure dosing accuracy, safe administration, and proper disposal of hazardous drugs.
The first review provided a flow chart, with explanations, for the management of oral liquids in practice (7). Due to the complexities involved in extemporaneously preparing oral liquids, it highlighted that (i) pharmacists should always consider a commercially available product (i. Stability studies in the literature allow for increased shelf-life and cost savings, in addition to providing evidence for stable products. Further, the recent availability of commercial liquid vehicles in many countries now provides pharmacists with a convenient resource for preparing an oral liquid formulation. It is also promising to note that procedures to prepare stable oral liquids from commercial solid dosage forms have been provided by manufacturers in cases where an oral liquid is not available or temporarily out of stock (Table 3) .
Alternatives to preparing oral liquids
The previous review (7) provided details on dispersing tablets or capsules in water or mixing them with food immediately prior to administration, and the provision of powder packets in cases where the preparation of oral liquid dosage forms are not feasible. The disadvantages of these methods were outlined, namely potential for dosing inaccuracies, poor palatability leading to adherence issues, and risks associated with carers or patients crushing tablets which should not be crushed (e.g. sustained release tablets). (68) . A risedronate sodium 35-mg tablet was added to a beaker and allowed to disintegrate without agitation. After two minutes, the water was stirred with a plastic spoon and an additional 4 oz of water was added to each beaker and stirred briskly for 30 seconds. The recommended amount of each food thickener was then added to each beaker. The risedronate tablets were shown to be stable for 24 hours with each of the food thickeners.
CONCLUSION
Orals liquids for certain drugs are often not commercially available, due to market size and the many physicochemical factors that need to be considered when formulating a liquid dosage form (69) . Since the physicochemical stability of a drug does not confirm either its safety or efficacy in a patient, there are a number of factors, including exercising good judgement, that the pharmacist must take into account when deciding to compound an oral liquid (70) . The fact that the stability of an extemporaneous formulation prepared from commercially available products cannot be predicted based on a formulation using the pure drug powder, due to the effect of excipients, was highlighted in the previous review where 6 out of 83 (7.2%) oral liquids presented with stability concerns, largely due to drugexcipient interactions. This review, which includes 42 oral liquids extemporaneously prepared by modifying existing commercial dosage forms presents 6 out of the 42 orals liquids including the four APIs, clopidrogrel, lansoprazole , temozolomide, and mercaptopurine for discussion.
However, it must be noted that the research and skill base in compounding has evolved since the previous review and that many improvements have been made to address the various formulation and stability issues in preparing extemporaneous oral liquids, from commercially available products, which is now common practice.
This review thus presents more complex stability issues, where the authors have proposed the inclusion of specific ingredients (excipients) to address some of the stability problems that have been identified in the past, including: the pH adjustment of lansoprazole extemporaneous oral liquids by the addition of NaHCO3 and the commercial availability of an oral suspension; the inclusion of antioxidants in mercaptopurine oral liquid; the addition of povidone K-30 to prevent crystal growth and citric acid to optimise pH in temozolomide oral liquid; and the adjustment of storage conditions to prevent enantiomeric conversion of clopidogrel.
This improved understanding of the role of excipients in the stability of extemporaneously prepared oral liquids from commercially available products will allow the pharmacist to meet the challenge in making an informed judgement when asked to address the needs of patients requiring the compounding of oral liquids. Washington Significant microbial growth was observed in methylcellulose vehicle stored at 23-25 ºC after 7 days. 1a. Tablet modified to an oral liquid mixture 1b. Capsule modified to an oral liquid mixture 1c. Liquid-filled soft gelatin capsule modified to an oral liquid mixture 1d. I/V preparation modified to an oral liquid mixture 1e. Inhalation preparation modified to an oral liquid mixture 1f. Granular powder preparation modified to an oral liquid mixture 2a. Lack of a commercially available oral liquid (paediatric) formulation for dose adjustment according to body weight or swallowing difficulties 2b. Ease of administration due to swallowing difficulties 2c. Nasogastric, jejunal, or feeding tubes 2d. All of the above -i.e. oral liquid dosage form not commercially available; including patients requiring a non-standard dose. 2e. Commercial oral liquid dosage form discontinued or unavailable * Unpleasant sulfurous smell and taste of the drug resulting from the slow release of hydrogen sulfide gas. As a result, patients may experience nausea and vomiting and have difficulties adhering to either oral or inhalation therapy. 3a. Glass prescription bottles 3b. Plastic prescription bottles 3c. Plastic oral syringes 4a. Analysis of organoleptic properties (e.g. colour, odour, taste) and visual inspection of physical stability (e.g. signs of caking, ease of pouring/ redistribution, microbial growth) and analysis of apparent pH revealed no appreciable changes throughout the storage period.
